




The 1st Asia Pacific Congress on
**CONTROVERSIES TO CONSENSUS IN DIABETES,
OBESITY AND HYPERTENSION**



Shanghai • China • June 2-5, 2011



FIRST ANNOUNCEMENT

www.codhy.com/AP
codhyAP@codhy.com





Dear Friends and Colleagues,

We are proud to announce that the **1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)** will take place in Shanghai, China on June 2-5, 2011.

The success of the 1st and 2nd World CODHy Congresses, which took place in Europe, paved the way for the 1st locally oriented CODHy Congress, which was held in Buenos Aires in 2010.

The 1st Latin America CODHy Congress was a vibrant academic event with a regional focus and attracted approximately 2000 participants from 52 countries.

Academically, the 1st Asia Pacific CODHy Congress will raise the most dynamic and controversial topics facing clinicians in the fields of Diabetes, Obesity and Hypertension in an exciting debate forum. The Congress will promote excellence in these fields by seeking to shed light on ongoing and challenging debates and to bridge gaps between the expansion of information and its consolidation in clinical practice.

Allowing ample time for speaker-audience discussion, the Congress aims at reaching up-to-date and agreed-upon answers to ongoing debates even when data remains limited, through evidence-based medicine and expert opinion. Participants will have the opportunity to take part in this vibrant meeting which will facilitate discussions on the shared experiences and opinions of leading local and international experts.

The 1st Asia Pacific CODHy Congress will emphasise issues related to the region in terms of epidemiology, genetics, diagnostics, typical complications and distinctive responses to treatments.

Many of the Faculty members will be local in order to facilitate the involvement of a large number of participants in the debates and to discuss typical regional problems.

We invite you to participate in the 1st Asia Pacific CODHy Congress in Shanghai.

Sincerely,

Prof. **Markolf Hanefeld** • Prof. **Guang Ning** • Prof. **Itamar Raz** • Prof. **Shaukat M. Sadikot**

Co-Chairpersons



CO-CHAIRPERSONS

Prof. **Markolf Hanefeld**, Germany

Prof. **Itamar Raz**, Israel

Prof. **Guang Ning**, China

Prof. **Shaukat M. Sadikot**, India



ORGANIZING COMMITTEE

A. Ceriello, UK
J. Davidson, USA
R.A. DeFronzo, USA

S. Del Prato, Italy
V.A. Fonseca, USA
V. Hainer, Czech Republic

P. Home, UK
N. Hotta, Japan
W. Lee, Singapore

P.M. Nilsson, Sweden
A. Ramachandran, India



SCIENTIFIC COMMITTEE

M. Al-Arouj, Kuwait
R. Bitzur, Israel
B. Bonora, Italy
C. Cockram, Hong Kong
J.H. de Vries, The Netherlands
A. de Zeeuw, The Netherlands
M. Donath, Switzerland
R. Fagard, Belgium
B. Frier, UK
B. Gallwitz, Germany
E. Grossman, Israel

S. Heller, UK
B. Hirshberg, Israel
P. Iozzo, Italy
A. Kadir, Malaysia
A. Keidar, Israel
L. Keuky, Cambodia
A. Khan, Bangladesh
Y. Kun-Ho, Korea
M. Laakso, Finland
N.M. Lalic, Serbia

H. Lebowitz, USA
L.A. Leiter, Canada
J. Meigs, USA
L. Meneghini, USA
D. Micic, Serbia
A. Natali, Italy
M.A. Nauck, Germany
A.K. Nikousokhan, Iran
W. Nitayanant, Thailand
D. Pei, China

P. Pozzilli, Italy
M.T. Que, The Philippines
G. Schernthaner, Austria
E. Standl, Germany
P. Tønnesen, Denmark
D. Tschöpe, Germany
J. Tuomilehto, Finland
T. Vilsbøll, Denmark
R. Weiss, Israel
J.T. Woo, Korea
A. Zanchetti, Italy





PRELIMINARY SCIENTIFIC PROGRAM

Friday, June 3, 2011

	HALL A	HALL B	HALL C
08:15-10:00	PLENARY SESSION 1 FUTURE THERAPY Opening Remarks <ul style="list-style-type: none"> • Diabetes prevention vs. early diagnosis in Asia and worldwide • Metabolic benefits of incremental weight loss/The role of insulin resistance • Diabetes in Asia – Is it only the beta cell? • Recent trial to prevent CV disease: Is this the answer or has it created more questions? 		
10:00-10:30	<i>Coffee Break</i>		
10:30-12:00	SESSION 2 DIABETES THERAPY- FOCUS ON ASIA <ul style="list-style-type: none"> • First line therapy - Glucosidase INH vs. Metformin <i>Glucosidase INH / Metformin</i> • Second line therapy - GLP1 / DPP4 INH vs. Secretagougue / Insulin <i>GLP1 / DPP4 INH: Secretagougue / Insulin:</i> 	SESSION 6 CV RISK AND INSULIN RESISTANCE IN CHILDHOOD - ASIAN PERSEPECTIVE <ul style="list-style-type: none"> • The Australian perspective • Metabolic syndrome in children in Malaysia • Metabolic syndrome - Early life exposure 	SESSION 10 CARDIOMETABOLIC RISK ASSESSMENT AND METABOLIC SYNDROME CONTROVERSIES <ul style="list-style-type: none"> • Drug therapy for Pre Diabetes <i>Yes / No</i>
12:00-12:10	<i>Technical Break</i>		
12:10-13:00	SESSION 3 MEET THE PROFESSOR Quality control in Asia: Diabetes Obesity Hypertension	SESSION 7 MEET THE PROFESSOR Novel therapy for GDM in Asia	SESSION 11 MEET THE PROFESSOR Diabetes treatment: From trial to practice, does it work?
13:00-14:00	<i>Lunch Break</i>		
14:00-15:30	SESSION 4 INSULIN THERAPY IN T2D - ASIA VS. THE ROW <ul style="list-style-type: none"> • Initiation of insulin <i>Not too early / Not too late</i> • Combinations of Oral Hypoglycaemic (OAD) with long-acting analogs • Place of TZD in Asian diabetic patients 	SESSION 8 TREATMENT GOALS IN DIABETES <ul style="list-style-type: none"> • A1c for diagnosis and monitoring in Asia (How accurate is A1c in Asia?) • Individualized A1c targets • Should we aim to normalise A1c? <i>Pro / Con</i> 	SESSION 12 OPTIMISING DIABETES THERAPY <ul style="list-style-type: none"> • Programmed insulin dose calculation <i>Pro / Con</i> • Benefit of self-monitoring glucose control <i>Pro / Con</i> • Continuous glucose monitoring (CGM): For whom will it be beneficial?
15:30-16:00	<i>Coffee Break</i>		
16:00-17:30	SESSION 5 THERAPEUTIC APPROACH TO YOUTH WITH T2DM? IS IT EFFICIENT FOR ASIANS? <ul style="list-style-type: none"> • Insulin, metformin TZD, glucosidase INH • Combination therapy and lifestyle modifications (Based on preliminary results from TODAY study) • Type 1 Diabetes in Asia - Differences and similarities to the ROW • LADA in Asia 	SESSION 9 RENAL AWARENESS 2010-2011 RANDOMIZE CONTROL STUDIES TO PROTECT THE KIDNEY <ul style="list-style-type: none"> • PLANET • SHARP • VITAL 	SESSION 13 CARDIOVASCULAR RISK IN DIABETES FOCUSING ON GENETICS IN ASIA <ul style="list-style-type: none"> • Asian vs. Western diet • Multiple biomarker efficacy/safety score to monitor renal and CV protection in Diabetes



PRELIMINARY SCIENTIFIC PROGRAM

Saturday, June 4, 2011

	HALL A	HALL B	HALL C
08:30-10:00	SESSION 14 APPROACH TO PREVENTION OF DIABETES <ul style="list-style-type: none"> • Asian vs. European patients / De-Plan Project • High prevalence in the Gulf region • Difference in candidate gene for T2D in Asia 	SESSION 19 EXTRA GLYCAEMIC EFFECTS OF INCRETIN BASED THERAPY IN T2D <ul style="list-style-type: none"> • The heart • The brain • The vascular system • The kidney 	SESSION 24 DIABETIC DYSLIPIDEMIA - FOCUS ON ASIA <ul style="list-style-type: none"> • Statin or combination • Therapy for statin intolerance • HDL: unmet challenge
10:00-10:30	<i>Coffee Break</i>		
10:30-12:00	SESSION 15 THE DIABETIC FOOT: INTERDISCIPLINARY INTERVENTION, DO WE NEED REGIONAL GUIDELINES? <ul style="list-style-type: none"> • Vascular surgeon • Interventional radiologist • Orthopaedic specialist • Infectious disease specialist 	SESSION 20 NOVEL NEW THERAPY FOR DIABETES - FOCUS ON ASIA <ul style="list-style-type: none"> • SGLT2 inhibitor • Aspirin for primary prevention in Asia • Aspirin or other antiplatelet? 	SESSION 25 OBESITY IN ASIA: IS IT DIFFERENT FROM THE REST OF THE WORLD? <ul style="list-style-type: none"> • Do we need anti - obesity drugs? <i>Yes / No: lifestyle intervention only</i>
12:00-12:10	<i>Technical Break</i>		
12:10-13:00	SESSION 16 POSTER PRESENTATION	SESSION 21 POSTER PRESENTATION	SESSION 26 POSTER PRESENTATION
13:00-14:00	<i>Lunch Break</i>		
14:00-15:30	SESSION 17 NOVEL DRUGS FOR T2D IN ASIAN POPULATION <ul style="list-style-type: none"> • Efficacy • Safety • Hypoglycaemia and mortality 	SESSION 22 NOVEL DRUGS FOR MICRO-VASCULAR COMPLICATIONS	SESSION 27 HYPERTENSION CONTROVERSIES <ul style="list-style-type: none"> • Hypertension: how low should we go? • Pre-hypertension therapy <i>Yes / No</i>
15:30-16:00	<i>Coffee Break</i>		
16:00-17:30	SESSION 18 INDIVIDUALISED THERAPY IN ASIAN T2D PATIENTS <ul style="list-style-type: none"> • Are all Asian patients the same when it comes to Diabetes? Case reports: China India Australia Japan / Korea 	SESSION 23 EVIDENCE FROM CLINICAL TRIALS IN DIABETES <ul style="list-style-type: none"> • Effects of glucose control on cardiovascular disease (CVD) • Specific OHG effects on CVD • Lessons from failures and hazards in clinical trials • Differences in the Asian patient populations 	SESSION 28 BARIATRIC SURGERY IN OBESITY AND DIABETES - ASIA <ul style="list-style-type: none"> • Last resort in obese patients <i>Pro / Con</i> • Early in the obese patient with risk factors <i>Pro / Con</i>



PRELIMINARY SCIENTIFIC PROGRAM

Sunday, June 5, 2011

	HALL A	HALL B
08:30-10:00	PLENARY SESSION 29 THE METABOLIC SYNDROME <ul style="list-style-type: none">• Abdominal obesity in Asian vs. Caucasian population• BMI and longevity in Asian populations (e.g Japan)• Testosterone deficiency and metabolic syndrome	SESSION 30 HYPERTENSION
10:00-10:30	<i>Coffee Break</i>	
10:30-12:00	PLENARY SESSION 31 <ul style="list-style-type: none">• Reducing Oxidative Stress• Food vs. drugs• Prevention of T2DM: Call for early intervention• Diabetes and Cancer• Very long acting insulin / GLP1 as second or third line therapy for Diabetes	





GENERAL INFORMATION

DATES

June 2-5, 2011

LOCATION

Shanghai, China

REGISTRATION FEES

	Early Registration Until Feb 9, 2011	Late Registration from Feb 10 until May 24, 2011	From May 25, 2011 and On Site
Participants - Physicians and Scientists	€490	€550	€600
Residents*	€330	€380	€420
Nurses and Students	€150	€190	€220
Accompanying Persons		€140	

*Refers to non-tenured junior scientists. Registration form must be accompanied by documentation of residency or a letter from the head of department confirming their status. The letter should be on the department letterhead and addressed to the Registration Department of the Congress.

Note: Credit card payments (only) will be charged to your account in US\$ according to the rate of exchange to the Euro on the date of payment.

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

CONGRESS ORGANIZERS

Please do not hesitate to contact the Organizers for any additional information or assistance:

codhyAP@codhy.com

LIABILITY AND INSURANCE

The Congress Organizer cannot accept liability for personal accidents, nor loss of, or damage to private property of participants, either during or directly arising from the 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). Participants should make their own arrangements with respect to health and travel insurance.



codhyAP@codhy.com
www.codhy.com/AP

Headquarters and Administration:
53 Rothschild Boulevard, PO Box 68,
Tel Aviv 61000, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
Email: info@comtecmed.com

Comtec Spain:
Bailén, 95-97, pral. 1. a - 08009
Barcelona, Spain
Tel: +34-93-2081145
Fax: +34-93-4579291
Email: spain@comtecmed.com

Comtec China:
175 Xiang Yang Road South,
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
Email: china@comtecmed.com

